Sirolimus

interleukin 2 ; Mus musculus







29 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 32459545 Effect of In Vivo Expansion of Regulatory T Cells with IL-2/anti-IL-2 Antibody Complex Plus Rapamycin on Experimental Autoimmune Uveoretinitis. 2021 Nov 17 1
2 34912349 Impact of Graft-Resident Leucocytes on Treg Mediated Skin Graft Survival. 2021 1
3 24658577 Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation. 2014 2
4 25394722 Administration of low doses of IL-2 combined to rapamycin promotes allogeneic skin graft survival in mice. 2014 Dec 1
5 23670972 Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. 2013 Sep 1
6 23105977 Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock. 2012 Sep 1
7 20086156 Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. 2010 Mar 1
8 19332874 In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. 2009 Apr 13 2
9 18768852 Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice. 2008 Sep 15 1
10 17351648 Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. 2007 May 1
11 18089405 Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation. 2007 Dec 2
12 15010863 IL2-dependent phosphorylation of 40S ribosomal protein S6 is controlled by PI-3K/mTOR signalling in CTLL2 cells. 2004 Apr 1
13 11872661 Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. 2002 Mar 4
14 11935154 Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. 2002 Feb 2
15 11355896 Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. 2001 May-Jun 2
16 10605009 Glycine inhibits growth of T lymphocytes by an IL-2-independent mechanism. 2000 Jan 1 1
17 10376934 Requirement of PI3-kinase activity for the nuclear transport of prolactin in cloned murine T lymphocytes. 1999 Feb 1 1
18 9566798 The effect of cyclosporin A, FK506 and rapamycin on the murine contact sensitivity reaction. 1998 Apr 1
19 8943845 Interleukin-2 (IL-2) upregulates BAG-1 gene expression through serine-rich region within IL-2 receptor beta c chain. 1996 Dec 1 1
20 7721872 Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte. Evidence for inhibition of CREB/ATF binding activities. 1995 Apr 21 3
21 7728769 Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. 1995 May 1 1
22 7518620 Quantitative comparison of rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction. 1994 Jul 15 1
23 7520778 The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. 1994 Sep 1 2
24 7690317 Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation. 1993 Sep 1
25 8109837 Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition. 1993 Nov 30 7
26 8376945 Interleukin 2 activates extracellular signal-regulated protein kinase 2. 1993 Oct 1 1
27 1380162 Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. 1992 Aug 15 2
28 1723403 Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. 1991 Dec 1
29 1987692 Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. 1991 Jan 1